In This Section

San Antonio Breast Cancer Symposium 2023

UT Health San Antonio and the American Association for Cancer Research (AACR) are co-sponsors of the 2023 San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023, at the Henry B. Gonzalez Convention Center in San Antonio.

Each year, SABCS features the latest research in the prevention, diagnosis, and treatment of premalignant breast disease and breast cancer, including data from late-breaking clinical trials. The symposium attracts thousands of basic scientists, physician-scientists, clinical investigators, breast care providers, and advocates from around the world.


SABCS Program Director Kate Lathrop, MD, UT Health San Antonio, moderated the first press conference on Wednesday, December 6.

View the press conference

The following studies were presented:

Tucatinib Plus Trastuzumab Emtansine May Benefit Patients With Advanced or Metastatic HER2-positive Breast Cancer

  • Presented by Sara A. Hurvitz, MD, University of Washington, Fred Hutchinson Cancer Center

Neoadjuvant Chemotherapy May Help Some Breast Cancer Patients Skip Regional Nodal Irradiation

  • Presented by Eleftherios (Terry) Mamounas, MD, MPH, University of Central Florida, Orlando Health Cancer Institute


SABCS Co-director Carlos Arteaga, MD, FAACR, Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, moderated the second press conference on Thursday, December 7.

View the press conference

The following studies were presented:

Younger Postmenopausal Patients With Early-stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy

  • Presented by Reshma Jagsi , MD, DPhil, Emory University School of Medicine, Winship Cancer Institute of Emory University

Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer

  • Presented by Anne May, PhD, Julius Center for Health Sciences and Primary Care, University Medical Center

Patients with HR-positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence

  • Presented by Hatem A. Azim Jr., MD, PhD, Tecnológico de Monterrey


SABCS Co-director Virginia Kaklamani, MD, UT Health San Antonio, moderated the third and final press conference on Friday, December 8.

View the press conference

The following studies were presented:

Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients with Low-risk DCIS

  • Presented by Seema A. Khan, MD, Feinberg School of Medicine, Lurie Comprehensive Cancer Center of Northwestern University

Some Breast Cancer Survivors May Safely De-escalate Mammography Three Years After Surgery

  • Presented by Janet Dunn, PhD, University of Warwick

Potentially Targetable Fusion RNAs May Be More Common in Metastatic Breast Cancer Than Previously Realized

  • Presented by Nolan Priedigkeit, MD, PhD, Dana-Farber Cancer Institute, Broad Institute of MIT and Harvard


The following two late-breaking abstracts were presented during the press conference.

Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis

  • Presented by Sibylle Loibl, MD, PhD, German Breast Cancer Group

Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis

  • Presented by Komal L. Jhaveri, MD, Memorial Sloan Kettering Cancer Center